Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAHAMA: REGN22530 in Primary Open Angle Glaucoma or Ocular Hypertension
NCT07675824Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
A Phase 2 trial of REGN22530 in primary open-angle glaucoma (POAG), ocular hypertension, sponsored by Regeneron Pharmaceuticals. Started Sep 2026; status: recruiting.
02
Drugs
REGN22530
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT07675824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07675824.